Clinical trial of KX2 391 for skin disorders.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2019
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Psoriasis; Skin disorders
- Focus Adverse reactions
- Sponsors PharmaEssentia Corporation
- 06 Jun 2019 Preliminary results from a cohort of patients with psoriasis (n=6) presented in an Athenex media release.
- 15 Dec 2015 Status changed from planning to recruiting, as per Athenex media release.
- 05 Dec 2012 New trial record